Search research articles
Contact Us
Filters
Showing results (1-10 of 116) with videos related to
Page
of 12
Sort By:
Bulletin Du Cancer
|
November 6, 2024
Julien Hadoux
Bulletin Du Cancer
|
October 2, 2021
[Drug approval: Selpercatinib and pralsetinib - RET-altered thyroid cancer]
Baudouin Courtier, Julien Hadoux
Bulletin Du Cancer
|
October 11, 2022
[Drug approval: Cabozantinib monotherapy in advanced thyroid cancers refractory or not eligible for radioactive iodine treatment, after progression under previous systemic therapies]
Paul Matte, Julien Hadoux
Best Practice & Research. Clinical Endocrinology & Metabolism
|
September 16, 2017
Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer
Julien Hadoux, Martin Schlumberger
Bulletin Du Cancer
|
June 4, 2026
[Cabozantinib - unresectable or metastatic well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors after at least one prior line of systemic therapy other than somatostatin analogues]
Léopold Descharmes, Julien Hadoux
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 30, 2013
Bevacizumab and subtype-adapted chemotherapy backbone in neuroendocrine tumors
Julien Hadoux, Michel Ducreux
The Lancet. Oncology
|
January 21, 2023
Randomised controlled trials are feasible in anaplastic thyroid cancer
Livia Lamartina, Julien Hadoux
La Revue Du Praticien
|
December 5, 2018
Anaplastic cancer of the thyroid, a rare and very aggressive cancer
Martin Schlumberger, Julien Hadoux, Sophie Leboulleux
Presse Medicale (Paris, France : 1983)
|
March 23, 2011
[Lung cancer in never smoker: Epidemiology, molecular profiles and treatment]
Julien Hadoux, Benjamin Besse, David Planchard
Bulletin Du Cancer
|
November 8, 2012
[Thymic epithelial neoplasms: updates on diagnosis, staging, biology and management in France]
Julien Hadoux, Nicolas Girard, Benjamin Besse
Page
of 12
Search research articles
Search
Showing results (1-10 of 116) with videos related to
Sort By:
Page
of 12
Bulletin Du Cancer
|
November 6, 2024
Julien Hadoux
Bulletin Du Cancer
|
October 2, 2021
[Drug approval: Selpercatinib and pralsetinib - RET-altered thyroid cancer]
Baudouin Courtier, Julien Hadoux
Bulletin Du Cancer
|
October 11, 2022
[Drug approval: Cabozantinib monotherapy in advanced thyroid cancers refractory or not eligible for radioactive iodine treatment, after progression under previous systemic therapies]
Paul Matte, Julien Hadoux
Best Practice & Research. Clinical Endocrinology & Metabolism
|
September 16, 2017
Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer
Julien Hadoux, Martin Schlumberger
Bulletin Du Cancer
|
June 4, 2026
[Cabozantinib - unresectable or metastatic well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors after at least one prior line of systemic therapy other than somatostatin analogues]
Léopold Descharmes, Julien Hadoux
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 30, 2013
Bevacizumab and subtype-adapted chemotherapy backbone in neuroendocrine tumors
Julien Hadoux, Michel Ducreux
The Lancet. Oncology
|
January 21, 2023
Randomised controlled trials are feasible in anaplastic thyroid cancer
Livia Lamartina, Julien Hadoux
La Revue Du Praticien
|
December 5, 2018
Anaplastic cancer of the thyroid, a rare and very aggressive cancer
Martin Schlumberger, Julien Hadoux, Sophie Leboulleux
Presse Medicale (Paris, France : 1983)
|
March 23, 2011
[Lung cancer in never smoker: Epidemiology, molecular profiles and treatment]
Julien Hadoux, Benjamin Besse, David Planchard
Bulletin Du Cancer
|
November 8, 2012
[Thymic epithelial neoplasms: updates on diagnosis, staging, biology and management in France]
Julien Hadoux, Nicolas Girard, Benjamin Besse
Page
of 12